Category - Investments and funding

The Dangerous Bet Behind Big Pharma’s Silence

Why dismantling America’s biomedical innovation engine is a long-term threat to the very industry staying quiet about it. A recent piece by Steven Usdain, which was also highlighted by Holden Thorp, got me thinking: are...read more

From Experimentation to Execution: How 2025 Reset the Trajectory of Healthcare and What 2026 Will Demand

TL;DR 2025 shifted healthcare from experimentation to execution AI moved from tools to infrastructure 2026 will reward disciplined execution over vision Why this matters for precision medicine + generative AI This...read more

Stop Guessing. Start Diagnosing: The Marketing & Product-Market Fit Scorecard

I recently conducted a LinkedIn survey to understand why most startups fail. I asked “Most startups don’t fail because of a bad idea — they fail because founders ignore the warning signs. I’m curious — which of these do...read more

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

TLDR; The Value of Drugs for Rare Disease Indications May Be Higher Than You Think – Assets for Neurodevelopmental Disorders Alone May Be Worth Beyond USD $420B.

Category - Investments and funding

The Dangerous Bet Behind Big Pharma’s Silence

From Experimentation to Execution: How 2025 Reset the Trajectory of Healthcare and What 2026 Will Demand

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment

SCIMap: View Impact of Federal Health Research Cuts

2024 in Review

TLDR; The Value of Drugs for Rare Disease Indications May Be Higher Than You Think – Assets for Neurodevelopmental Disorders Alone May Be Worth Beyond USD $420B.

Velsera Is Building an Ecosystem that Accelerates the R&D Loop and Democratizes Omics Data to Propel the Next Era of Precision Medicine

Goodbye 2022 – Hello 2023

Time Is What We Want Most – Why Wasting Any More of It?

Deepcell Aims to Create a Single Cell Morpholome Platform

We Invite you to join enlightenbio’s Subject Matter Expert Network!

Genomenon Raises $20M Series B Financing, Launching a New Era in AI-Powered Genomic Data

Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease

Color announces Series E financing, at a valuation of $4.6 billion, to accelerate expansion of accessible and equitable public health infrastructure

Armonica Technologies Closes B Round Financing

Genome Medical Announces Acquisition of GeneMatters and Closing of $60 Million Series C Financing

Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing

Helix Announces $50 Million Series C Funding to Continue Acceleration into Clinical Population Genomics and COVID-19 Viral Surveillance